DUBLIN – It's not a bad parting gift to receive as you exit the sector. Shares in synthetic biology specialist Evolva Holding SA got a 9 percent boost Thursday on news that it landed a $6.5 million contract from the U.S. Defense Threat Reduction Agency (DTRA) to carry out preclinical research on its GC-072 program.